March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

Haleon has named Nathalie Gerschtein as president North America, following Lisa Paley’s announcement to step down from her role. Gerschtein said, “I am honored to join Haleon at such an ...

Haleon is to axe diversity targets from its executive bonus scheme in the latest sign that UK businesses are rowing back on DEI. The Sensodyne-maker has confirmed that its chief executive and ...

Pfizer (NYSE:PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE:HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

(RTTNews) - Pfizer Inc. (PFE) announced the sales of around 618 million ordinary shares in Haleon plc (HLN) at a price of 385 pence or about $5.01 per Ordinary Share for gross proceeds of ...

Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each.

In a report released on March 20, Karel Zoete from Kepler Capital maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of p440.00. The company’s shares closed ...